
VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium
Ella Day | July 14, 2025 | News story | Medical Communications, Research and Development | Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing for Swiss radiopharma company, Nuclidium. The company will use the funds to advance the development of its Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline, applicable to multiple oncology indications.
The funding round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners and Neva SGR, with DeepTech & Climate Fonds, Bayern Kapital, Eurazeo, NRW.BANK and HighLight Capital, participating alongside VIVES Partners.
VIVES Partners connects academic research and upcoming projects with public and private investors, supporting the development of start-ups into projects with high-impact. The contribution marks the company’s first participation in the radiopharma field and is its largest to date.
Nuclidium’s platform links tumour-targeting molecules with copper isotopes to address the current limitations in radiotheranostics. Its leading candidates are intended for diagnosing and treating metastatic prostate, neuroendocrine tumours and breast cancer.
Sandra Schoors, partner at VIVES Partners, said: “We have a strong belief in the potential of Nuclidium’s copper-based platform as a new radiotheranostic.”
Ella Day
14/7/25






